Company

Bayer's Sunharbo (Asundexian) Secures NMPA Approval in China – World's First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA
BayerETR: BAYN

Bayer’s Sunharbo (Asundexian) Secures NMPA Approval in China – World’s First‑in‑Class FXIa Inhibitor to Reduce Stroke Risk After Ischemic Stroke or High‑Risk TIA

Bayer AG (ETR: BAYN) announced that China's National Medical Products Administration (NMPA) has approved Sunharbo (asundexian tablets), the world's first (first‑in‑class) activated Factor XI (FXIa) inhibitor, for reducing the risk…

Hansoh Pharma Pledges RMB 100 Million Donation to the China Foundation for Science and Technology Development – Strategic Partnership to Fund Scientific Innovation, Talent Development and Health Communication

Hansoh Pharma Pledges RMB 100 Million Donation to the China Foundation for Science and Technology Development – Strategic Partnership to Fund Scientific Innovation, Talent Development and Health Communication

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

AbbVie Launches Epkinly (Epcoritamab) in China – First Bispecific Antibody Approved by NMPA for Relapsed/Refractory Follicular Lymphoma in the Second‑Line and Beyond

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers
ADC / XDCAsieris Pharmaceuticals

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline
Novo NordiskNYSE: NVO

Novo Nordisk Completes Restructuring With Over DKK 10 Billion in Cost Savings – Semaglutide Growth Pressure Drives Pivot Toward CagriSema and a Five‑Blockbuster Pipeline

Jenscare's JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market
HKG: 9877Jenscare Scientific

Jenscare’s JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market

Roche Reports Positive Phase II Topline Data for Enicepatide – Once‑Weekly GLP‑1/GIP Agonist Cuts HbA1c by 2.65% and Body Weight by 15.5% at 48 Weeks
Clinical trial resultsObesity

Roche Reports Positive Phase II Topline Data for Enicepatide – Once‑Weekly GLP‑1/GIP Agonist Cuts HbA1c by 2.65% and Body Weight by 15.5% at 48 Weeks

Show More